EFFER-K 20 MEQ UNFLAVORED
(+3 other brands)
Drug Facts
Composition & Profile
Identifiers & Packaging
How Supplied Each tablet of Effer-K ® 10 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) in solution provides 10 mEq (391 mg) of elemental potassium as potassium citrate. Each tablet of Effer-K ® 20 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) in solution provides 20 mEq (782 mg) of elemental potassium as potassium citrate. Store below 40°C (104°F), preferably between 15° and 30°C (59° and 86°F), in original hermetic package. The 10 mEq tablets are 11/16 inch diameter round, flat face on both sides with large bevels. EK 10 is imprinted on one side of the tablet. Each tablet is pouched with the product description on one side of the pouch and the lot number, expiration date and barcode on the other. The 20 mEq tablets are 7/8 inch diameter round, flat face on both sides with large bevels. EK 20 is imprinted on one side of the tablet. Each tablet is pouched with the product description on one side of the pouch and the lot number, expiration date and barcode on the other. NDC 51801-01330 Unflavored, 10 mEq, package of 30 tablets NDC 51801-01430 Cherry Vanilla, 10 mEq, package of 30 tablets NDC 51801-01130 Unflavored, 20 mEq, package of 30 tablets NDC 51801-01230 Orange Cream, 20 mEq, package of 30 tablets Nomax, Inc. St. Louis, MO 63123 - Made in USA MSN 015-183 Rev. 05/12; PRINCIPAL DISPLAY PANEL - 10mEq Tablet Pouch Carton - Unflavored NDC 51801-013-30 30 Tablets Effer-K ® 10mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 10mEq (391mg) of potassium in solution as potassium citrate. Unflavored Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 10mEq Tablet Pouch Carton - Unflavored; PRINCIPAL DISPLAY PANEL - 10 mEq Tablet Pouch Carton - Cherry Vanilla NDC 51801-014-30 30 Tablets Effer-K ® 10 mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 10mEq (391mg) of potassium in solution as potassium citrate. Cherry Vanilla Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 10 mEq Tablet Pouch Carton - Cherry Vanilla; PRINCIPAL DISPLAY PANEL - 20 mEq Tablet Pouch Carton - Unflavored NDC 51801-011-30 30 Tablets Effer-K ® 20 mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 20mEq (782mg) of potassium in solution as potassium citrate. Unflavored Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 20 mEq Tablet Pouch Carton - Unflavored; PRINCIPAL DISPLAY PANEL - 20mEq Tablet Pouch Carton - Orange Cream NDC 51801-012-30 30 Tablets Effer-K ® 20mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 20mEq (782mg) of potassium in solution as potassium citrate. Orange Cream Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 20mEq Tablet Pouch Carton - Orange Cream
- How Supplied Each tablet of Effer-K ® 10 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) in solution provides 10 mEq (391 mg) of elemental potassium as potassium citrate. Each tablet of Effer-K ® 20 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) in solution provides 20 mEq (782 mg) of elemental potassium as potassium citrate. Store below 40°C (104°F), preferably between 15° and 30°C (59° and 86°F), in original hermetic package. The 10 mEq tablets are 11/16 inch diameter round, flat face on both sides with large bevels. EK 10 is imprinted on one side of the tablet. Each tablet is pouched with the product description on one side of the pouch and the lot number, expiration date and barcode on the other. The 20 mEq tablets are 7/8 inch diameter round, flat face on both sides with large bevels. EK 20 is imprinted on one side of the tablet. Each tablet is pouched with the product description on one side of the pouch and the lot number, expiration date and barcode on the other. NDC 51801-01330 Unflavored, 10 mEq, package of 30 tablets NDC 51801-01430 Cherry Vanilla, 10 mEq, package of 30 tablets NDC 51801-01130 Unflavored, 20 mEq, package of 30 tablets NDC 51801-01230 Orange Cream, 20 mEq, package of 30 tablets Nomax, Inc. St. Louis, MO 63123 - Made in USA MSN 015-183 Rev. 05/12
- PRINCIPAL DISPLAY PANEL - 10mEq Tablet Pouch Carton - Unflavored NDC 51801-013-30 30 Tablets Effer-K ® 10mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 10mEq (391mg) of potassium in solution as potassium citrate. Unflavored Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 10mEq Tablet Pouch Carton - Unflavored
- PRINCIPAL DISPLAY PANEL - 10 mEq Tablet Pouch Carton - Cherry Vanilla NDC 51801-014-30 30 Tablets Effer-K ® 10 mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 10mEq (391mg) of potassium in solution as potassium citrate. Cherry Vanilla Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 10 mEq Tablet Pouch Carton - Cherry Vanilla
- PRINCIPAL DISPLAY PANEL - 20 mEq Tablet Pouch Carton - Unflavored NDC 51801-011-30 30 Tablets Effer-K ® 20 mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 20mEq (782mg) of potassium in solution as potassium citrate. Unflavored Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 20 mEq Tablet Pouch Carton - Unflavored
- PRINCIPAL DISPLAY PANEL - 20mEq Tablet Pouch Carton - Orange Cream NDC 51801-012-30 30 Tablets Effer-K ® 20mEq Tablets POTASSIUM BICARBONATE / CITRIC ACID EFFERVESCENT TABLETS FOR ORAL SOLUTION, USP Upon effervescing, each tablet provides 20mEq (782mg) of potassium in solution as potassium citrate. Orange Cream Rx Only nomax inc PRINCIPAL DISPLAY PANEL - 20mEq Tablet Pouch Carton - Orange Cream
Overview
Effer-K ® 10mEq and 20 mEq Tablets (Effervescent Potassium Bicarbonate/ Citric Acid Tablets for Oral Solution, USP) are intended for the preparation of an oral solution of potassium. Each 10 mEq tablet contains 1.0g potassium bicarbonate and 0.84g citric acid which, after effervescing, provides a solution containing 10 mEq (391 mg) of elemental potassium as potassium citrate. Each 20 mEq tablet contains 2.0g potassium bicarbonate and 1.68g citric acid which, after effervescing, provides a solution containing 20 mEq (782 mg) of elemental potassium as potassium citrate. Tablets also contain maltodextrin, anhydrous dextrose and l-leucine. In addition, the flavored tablets contain SD flavors, and sucralose. The 10 mEq Cherry Vanilla tablets contain FD&C Red #40 and the 20 mEq Orange Cream tablets contain FD&C Yellow #6 and FD&C Red #40. The Unflavored 10 and 20 mEq tablets do not contain any natural or synthetic dyes, flavors or sweeteners. The 10 mEq tablets are 11/16 inch diameter round, flat face on both sides with large bevels. EK 10 is imprinted on one side. The 20 mEq tablets are 7/8 inch diameter round, flat face on both sides with large bevels. EK 20 is imprinted on one side. Each tablet is pouched with the product description on one side of the pouch and the lot number, expiration date and bar code on the other
Indications & Usage
For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassium-losing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated.
Dosage & Administration
Effer-K ® 10 mEq. Adults - one tablet (Cherry Vanilla or Unflavored) each containing 10 mEq. (391 mg) of elemental potassium, 1 to 4 times daily, depending on the requirement of the patient. Completely dissolve the Cherry Vanilla flavored tablet in 2 to 3 ounces (58 to 85 mL) of cold or ice water before drinking. Completely dissolve the Unflavored tablet in 2 to 3 ounces (58 to 85 mL) of cold juice of choice before drinking. Effer-K ® 20 mEq. Adults - one tablet (Orange Cream or Unflavored) each containing 20 mEq. (782 mg) of elemental potassium, 1 to 4 times daily, depending on the requirement of the patient. Completely dissolve the Orange Cream flavored tablet in 3 to 4 ounces (85 to 115 mL) of cold or ice water before drinking. Completely dissolved the Unflavored tablet in 3 to 4 ounces (85 to 115 mL) of cold juice of choice before drinking. NOTE: It is suggested that any effervescent potassium tablet be taken with meals and sipped slowly over a 5 to 10 minute period.
Warnings & Precautions
Warnings In patients with hyperkalemia and impaired mechanisms for excreting potassium the administration of potassium salts can produce hyperkalemia and cardiac arrest. This occurs most commonly in patients given potassium by the intravenous route but may also occur in patients given potassium orally. Potentially fatal hyperkalemia can develop rapidly and be asymptomatic. The use of potassium salts in patients with chronic renal disease, or any other condition which impairs potassium excretion, requires particularly careful monitoring of the serum potassium concentration and appropriate dosage adjustment. Note: There is no conclusive evidence that potassium supplements lower blood pressure in hypertensive patients.
Contraindications
Potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in such patients can produce cardiac arrest. Conditions predisposing to hyperkalemia include: chronic renal failure, acute metabolic acidosis, uncontrolled diabetes mellitus, esophageal compression or delayed gastric emptying or intestinal obstruction/stricture or peptic ulcer. Potassium supplements should be used with caution and only where medically indicated in patients with familial periodic paralysis, myotonia congenita or severe/complete heart block. IMPORTANT: Potassium supplements are contraindicated in patients receiving potassium-sparing diuretics (e.g. spironolactone, triamterene) since such use may produce severe hyperkalemia.
Adverse Reactions
One of the most severe adverse effects is hyperkalemia (see Contraindications , Warnings and Overdosage ). The most common adverse reactions to oral potassium salts are nausea, vomiting, abdominal discomfort, and diarrhea. These symptoms are due to irritation of the gastrointestinal tract and are best managed by diluting the preparation further, taking the dose with meals, or reducing the dose. Skin rash has been reported rarely.
Drug Interactions
The simultaneous administration of potassium supplements and a potassium-sparing diuretic can produce severe hyperkalemia (see Contraindications ). Potassium supplements should be used cautiously in patients who are using salt substitutes, because most of the latter contain substantial amounts of potassium. Such concomitant use could result in hyperkalemia. Moreover, the following drugs may produce unfavorable interactions when used concomitantly with potassium supplements: angiotension-converting enzyme (ACE) inhibitors, nonsteroid anti-inflammatory drugs (NSAIDs), beta-adrenergic blocking drugs, heparin, low-salt foods, other potassium containing medications, digitalis glycosides and others.
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.